Slingshot members are tracking this event:

Bristol Myers Squibb (BMY) Reports Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Survival Results in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 19, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Opdivo, Nivolumab, Cabometyx, Cabozantib, Renal Cell Carcinoma, Cabozantinib, Checkmate